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A dual specificity kinase, DYRK1A, 
as a potential therapeutic target 
for head and neck squamous cell 
carcinoma
Aneesha Radhakrishnan1,2, Vishalakshi Nanjappa1,3, Remya Raja1, Gajanan Sathe1,4, 
Vinuth N. Puttamallesh1,3, Ankit P. Jain1,5, Sneha M. Pinto1, Sai A. Balaji6, 
Sandip Chavan1,4, Nandini A. Sahasrabuddhe1, Premendu P. Mathur2,5, Mahesh M. Kumar7, 
T. S. Keshava Prasad1,3,8, Vani Santosh9, Geethanjali Sukumar1, Joseph A. Califano10,11, 
Annapoorni Rangarajan6, David Sidransky11, Akhilesh Pandey12,13,14,15, Harsha Gowda1,8  
& Aditi Chatterjee1,8
Despite advances in clinical management, 5-year survival rate in patients with late-stage head and 
neck squamous cell carcinoma (HNSCC) has not improved significantly over the past decade. Targeted 
therapies have emerged as one of the most promising approaches to treat several malignancies. Though 
tyrosine phosphorylation accounts for a minority of total phosphorylation, it is critical for activation of 
signaling pathways and plays a significant role in driving cancers. To identify activated tyrosine kinase 
signaling pathways in HNSCC, we compared the phosphotyrosine profiles of a panel of HNSCC cell lines 
to a normal oral keratinocyte cell line. Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 
1A (DYRK1A) was one of the kinases hyperphosphorylated at Tyr-321 in all HNSCC cell lines. Inhibition 
of DYRK1A resulted in an increased apoptosis and decrease in invasion and colony formation ability 
of HNSCC cell lines. Further, administration of the small molecular inhibitor against DYRK1A in mice 
bearing HNSCC xenograft tumors induced regression of tumor growth. Immunohistochemical labeling 
of DYRK1A in primary tumor tissues using tissue microarrays revealed strong to moderate staining of 
DYRK1A in 97.5% (39/40) of HNSCC tissues analyzed. Taken together our results suggest that DYRK1A 
could be a novel therapeutic target in HNSCC.
Squamous cell carcinoma of head and neck (SCCHN) is a common malignancy worldwide arising from var-
ious regions of upper-aero digestive tract and oral cavity. It is the sixth most common cancer worldwide1. 
Approximately more than 500,000 new cases and 12,000 deaths are estimated annually in United States for 
head and neck cancer2. The major risk factors in HNSCC include smoking, alcohol consumption and human 
1Institute of Bioinformatics, International Technology Park, Bangalore, 560 066, India. 2Department of Biochemistry 
and Molecular Biology, Pondicherry University, Puducherry 605014, India. 3Amrita School of Biotechnology, 
Amrita University, Kollam 690 525, India. 4Manipal University, Madhav Nagar, Manipal 576104, India. 5School of 
Biotechnology, KIIT University, Bhubaneswar 751024, India. 6Department of Molecular Reproduction, Development 
and Genetics, Indian Institute of Science, Bangalore, 560012, India. 7Department of Neuro-Virology, National 
Institute of Mental Health and Neurosciences, Bangalore 560029, India. 8YU-IOB Center for Systems Biology and 
Molecular Medicine, Yenepoya University, Mangalore 575018, India. 9Department of Pathology, National Institute 
of Mental Health and Neurosciences, Bangalore 560029, India. 10Milton J. Dance Head and Neck Center, Greater 
Baltimore Medical Center, Baltimore, MD 21204, USA. 11Department of Otolaryngology-Head and Neck Surgery, 
Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA. 12McKusick-Nathans Institute of Genetic 
Medicine,Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. 13Department of Biological 
Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. 14Department of Oncology, 
Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. 15Department of Pathology, Johns 
Hopkins University School of Medicine, Baltimore, MD 21205, USA. Correspondence and requests for materials 
should be addressed to H.G. (email: harsha@ibioinformatics.org) or A.C. (email: aditi@ibioinformatics.org)
Received: 14 April 2016
Accepted: 10 October 2016
Published: 31 October 2016
OPEN
www.nature.com/scientificreports/
2Scientific REPORts | 6:36132 | DOI: 10.1038/srep36132
papillomavirus (HPV) infections. Despite all the treatment strategies, therapeutic resistance/failure and tumor 
recurrence still exists making the five-year survival rate, sub-optimal3. Hence it is important to understand the 
molecular events associated with HNSCC for the identification of novel therapeutic targets.
Protein kinases are the key regulators of signal transduction pathways in many cellular processes. Aberrant 
activation of kinase driven pathways has been reported to play a crucial role in multiple cellular processes that 
leads to cancer progression. Such alterations can be assessed by studying the proteome through analysis of the 
phosphoproteome. In recent years, kinases have become one of the most intensively studied groups of proteins 
as drug targets. To date, 28 small molecule kinase inhibitors have been approved by FDA for cancer therapy4. 
Identification of imatinib, a small molecule inhibitor against BCR-ABL tyrosine kinase, by Druker and colleagues 
revolutionized the treatment of patients with chronic myeloid leukemia5,6. Although targeted therapy using EGFR 
specific antibody cetuximab, is used in the treatment of HNSCC; non-responsiveness and development of resist-
ance is a common hindrance7. Protein kinases not only play a central role in cell signaling networks but also 
serve as excellent therapeutic targets. Phosphoproteome profiling to identify activated kinase pathways is an 
established approach to identify novel therapeutic targets in cancer8. To achieve this, we studied the activation of 
signaling molecules in a panel of HNSCC cell lines and a normal oral keratinocyte cell line (OKF6/TERT1) using 
phosphoproteomics approach. We identified a total of 38 proteins which included multiple kinases which were 
found to be differentially phosphorylated in all the HNSCC cell lines compared to the normal oral keratinocyte 
cell line, OKF6/TERT1. Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) was one 
of the identified kinases which showed hyperphosphorylation (fold change ≥ 1.5) in all the 6 HNSCC cell lines 
compared to normal oral keratinocytes.
DYRK1A belongs to dual specificity tyrosine (Y) phosphorylation regulated kinase (DYRK) family which is 
known to be activated through autophosphorylation of tyrosine residues in the activation loop and phosphorylates 
their substrates on serine and threonine residues9. Other members of this family include DYRK1B, DYRK2, 
DYRK3, DYRK4A and DYRK4B. Studies have revealed that DYRK family kinases play an important role in reg-
ulating cell proliferation and apoptosis10,11. DYRK1A has been reported to be strongly expressed in the brain and 
known to regulate various functions in brain12. However, studies by other groups have reported overexpression of 
DYRK1A, and its closest member DYRK1B, in various tumors including glioblastoma, ovarian cancer, lung can-
cer, colon cancer and pancreatic cancer13–17 suggesting a role of this molecule in tumorigenesis. A study by Pozo 
et al., showed that inhibition of DYRK1A stimulated EGFR degradation and reduced EGFR-dependent tumor 
growth in glioblastoma13. DYRK1A plays an important role in cell survival by phosphorylating caspase 9 at Thr-
125 and inhibiting its action in apoptosis11. Taken together these studies indicate that DYRK1A plays a significant 
role in mediating survival of cancer cells. Although the role of DYRK1A in cancers has been characterized, its role 
in HNSCC is not defined. In this study, we have assessed the role of DYRK1A as a potential therapeutic target in 
HNSCC.
Results
Quantitative phosphotyrosine analysis of HNSCC. We employed tandem mass tag (TMT)-based 
labeling technology coupled with anti-phosphotyrosine antibody-based enrichment approach to identify dif-
ferentially phosphorylated proteins between normal oral keratinocyte OKF6/TERT1, and a panel of HNSCC 
cell lines (JHU-O11, JHU-O22, JHU-O28, JHU-O29, FaDu and CAL 27) (Supplementary Fig. 1). We identified 
a total of 51 phosphosites in 38 proteins in the HNSCC cells compared to OKF6/TERT1. Amongst the hyper-
phosphorylated proteins, we identified molecules including protein tyrosine phosphatase, non-receptor type 11 
(PTPN11), myelin protein zero-like 1 (MPZL1) and tyrosine kinases such as LYN proto-oncogene (LYN), EPH 
receptor A2 (EPHA2) and DYRK1A. The overexpression of PTPN11, LYN and EPHA2 has been reported in head 
and neck cancer18–20. Tyr-321 is the known activation site of DYRK1A21. We identified hyperphosphorylation of 
DYRK1A at Tyr-321 in all HNSCC cell lines. As expected, protein phosphorylation pattern was heterogeneous 
across HNSCC cell lines (Table 1). Western blot analysis revealed overexpression of DYRK1A in HNSCC cell lines 
compared to OKF6/TERT1 (Fig. 1a).
Immunohistochemical validation of DYRK1A in HNSCC tissue. Our western blot results revealed 
overexpression of DYRK1A in HNSCC cell lines. We checked the expression of DYRK1A in primary HNSCC 
tissues. Tissue microarray-based immunohistochemical validation was carried out using 40 HNSCC tissues. A 
variable staining pattern was noted across cases of HNSCC. 97.5% (39 of 40) of HNSCC cases showed moderate 
to strong staining (1+ to 2+ ) while 2.5% (1 of 40) of the cases showed negative staining. A Chi-square test clearly 
indicated a significant overexpression of DYRK1A in HNSCC cases (p-value = 0.0076). The results of the immu-
nohistochemical validation are provided in Table 2. The representative staining patterns for DYRK1A in HNSCC 
and adjacent normal tissues are illustrated in Fig. 1b.
Inhibition of DYRK1A reduces cellular proliferation in HNSCC. Since DYRK1A was found to be 
overexpressed in all the HNSCC cell lines, we next studied the role of DYRK1A in cell proliferation. Cellular 
proliferation for the panel of HNSCC cell lines was studied after silencing of endogenous expression of DYRK1A 
using its specific siRNA. Western blot analysis confirmed efficient knockdown of DYRK1A in all HNSCC 
cells (Fig. 1c). We further assessed the effect of DYRK1A silencing on cell proliferation of HNSCC cell lines. A 
decrease in cellular proliferation of HNSCC cells was observed upon silencing of DYRK1A (Fig. 1d). Akin to 
siRNA results, inhibition of DYRK1A using its specific inhibitor harmine22 also led to decrease in the cellular 
proliferation of majority of the HNSCC cells (Supplementary Fig. 2).
Inhibition of DYRK1A reduces the colony forming ability of HNSCC cells. Having observed that 
DYRK1A plays an essential role in cellular proliferation, we next studied the role of DYRK1A in the colony 
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forming ability of the HNSCC cells. siRNA mediated silencing of DYRK1A resulted in a decrease in the colony 
forming ability of the HNSCC cells (Fig. 2a,b). In concordance with the siRNA results, inhibition of DYRK1A 
using harmine in HNSCC cell lines resulted in a significant decrease in the colony formation ability of the cells 
(Fig. 2c,d).
Inhibition of DYRK1A reduces the invasive ability of the HNSCC cells. Since inhibition of DYRK1A 
led to a decrease in the colony formation ability of the HNSCC cell lines, we next studied if DYRK1A has a poten-
tial role in HNSCC invasiveness. We investigated the in vitro invasive capabilities of the HNSCC cells using 
Matrigel invasion assay. siRNA mediated silencing of DYRK1A, showed decrease in invasive property of all the 
HNSCC cells (Fig. 3a,b). In agreement with the siRNA results, inhibition of DYRK1A with harmine, resulted in a 
significant decrease in the invasive property of all the HNSCC cells (Fig. 3c,d). Taken together, our results indicate 
that DYRK1A may play an essential role in HNSCC metastasis.
Inhibition of DYRK1A suppresses tumor growth in vivo. Having observed DYRK1A affects both 
HNSCC cellular proliferation and invasive potential in vitro, we next studied the oncogenic potential of DYRK1A 
by targeting DYRK1A in vivo. Athymic nude mice were injected subcutaneously (s.c.) with CAL 27 cells. At day 7, 
when the tumors reached the size of approximately 50 mm3, mice were randomized into two groups of five ani-
mals each and treated with either vehicle alone (DMSO) or harmine (15 mg/kg/injection, every 3 days till 3 
weeks) intraperitoneally (i.p.). Tumor size was measured every 3 days and the mean tumor volume was calcu-
lated. We observed significant differences in tumor growth between vehicle control and harmine treated group 
over a 25-day experimental period (Fig. 4a). The mice were sacrificed at the end of 25 days and tumors extracted 
from harmine treated group had significant lower tumor mass compared to vehicle group (Fig. 4b,c). Further we 
examined the expression of proliferation marker, Ki67 in xenograft sections using immunofluorescence. The data 
revealed a decrease in expression of Ki67 in harmine treated xenograft tissue compared to vehicle treated tissue 
(Fig. 4d).
Inhibition of DYRK1A induces apoptosis in vitro and in vivo. Next we studied the role of inhibition 
DYRK1A in apoptosis in HNSCC cells. CAL 27 and JHU – O28 were treated with harmine or DMSO (control) 
and apoptosis was determined by staining cells using annexin V fluorescein isothiocyanate and propidium iodide 
(PI). Harmine treatment induced 14.8% late apoptosis (both annexin V and PI positive) in CAL 27 cells, with 
6.0% of cells undergoing early apoptosis (annexin V positive and PI negative), compared to 3.7% late apoptotic 
cells and 1.7% of early apoptotic cells in the control (DMSO treated) cells (Fig. 5a). In JHU-O28 cells harmine 
treatment induced 10.8% and 1.7% of late and early apoptosis respectively compared to 5.5% and 1.1% late and 
early apoptotic cells respectively in the control (DMSO) treated cells (Fig. 5b). In addition, we examined the 
expression of pro and anti-apoptotic proteins upon inhibition of DYRK1A in CAL 27 and JHU-O28 cells. Western 
blot analyses revealed a decrease in BCL-xL and an increased expression of BAX upon inhibition of DYRK1A 
with harmine (Fig. 5c). Treatment with harmine also resulted in the activation of CASP9 (Caspase-9) and PARP 
(Poly (ADP-ribose) polymerase) in both CAL 27 and JHU-O28 cells (Fig. 5c). Further we studied the expres-
sion of pro and anti-apoptotic proteins in the xenograft tissue treated with either vehicle control (DMSO) or 
harmine. Western blot analysis revealed a decrease in the expression of both BCL-xL and BCL2 and an increased 
expression of pro-apoptotic protein BAX (Fig. 5d). In vivo treatment with harmine also promoted the activation 
of CASP9, CASP3 (Caspase 3) and PARP indicating induction of apoptosis (Fig. 5d). These results indicate that 
inhibition of DYRK1A leads to induction of apoptosis in HNSCC cells.
Gene 





















CDK1 IGEGtyGVVYK Cyclin-dependent kinase 1 T14; Y15 26.6 8.4 11.8 8.3 16.3 13.2
CAV1 YVDSEGHLyTVPIR Caveolin-1 Y14 1.2 1.7 2.9 3.7 1.1 1.8
LYN VIEDNEYtAR Tyrosine-protein kinase Lyn T377 1.8 2.6 9.7 6.6 4.4 6.9
EGFR GSTAENAEyLR Epidermal growth factor receptor Y1197 1.0 1.6 5.7 19.9 3.7 7.1
MPZL1 SESVVyADIR Myelin protein zero like protein 1 Y113 6.4 1.5 3.2 2.1 1.1 4.1











Y321 1.8 2.7 3.8 2.1 2.9 3.8
CTNND1 SLDNNySTPNER Catenin delta-1 Y797 0.2 1.2 4.3 3.6 1.7 7.0
ANXA2 SYSPyDMLESIR Annexin A2 Y238 0.6 1.6 7.7 0.9 1.8 3.2
Table 1.  A partial list of hyperphosphorylated proteins in at least four cell lines.
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Figure 1. Inhibition of DYRK1A reduces cellular proliferation in HNSCC. (a) Western blot analysis shows 
the expression profile of DYRK1A in a panel of HNSCC cell lines – JHU-O11, JHU-O22, JHU-O28, JHU-O29, 
FaDu and CAL 27 compared to normal oral keratinocytes OKF6/TERT1. (b) Immunohistochemical validation 
of DYRK1A in HNSCC tissue - representative sections from normal and HNSCC cases were stained with 
anti-DYRK1A antibody. (c) Western blot analysis depicting DYRK1A expression in HNSCC cell lines upon 
transfection with DYRK1A siRNA. β -actin was used as a loading control. (d) Cellular proliferation of HNSCC 
cells upon siRNA mediated silencing of DYRK1A (*p < 0.05).
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Inhibition of DYRK1A leads to activation of FOXO3A in HNSCC. Since our in vitro and in vivo results 
showed that DYRK1A plays an essential role in the oncogenic potential of HNSCC, we sought to study the signal-
ing mechanisms of DYRK1A in HNSCC. Previous studies have shown activation of AKT and MAPKs in the brain 
of DYRK1A-overexpressing mice23. It has also been reported that DYRK1A phosphorylates forkhead transcrip-
tion factors and mediates cell survival24,25. FOXO3A is a known substrate of AKT and MAPK and studies have 
shown that phosphorylation of FOXO3A by AKT and MAPKs are inhibitory and helps in the survival of cancer 
cells26,27. Inhibition of DYRK1A using harmine decreased p-AKT levels without affecting the total AKT levels in 
three of the HNSCC cell lines studied (Fig. 6a,b). As AKT is reported to phosphorylate FOXO3A on Ser25328, we 
examined the effect of DYRK1A-AKT pathway on FOXO3A phosphorylation. Inhibition of DYRK1A decreased 
phosphorylation of FOXO3A on Ser253 in all HNSCC cell lines (Fig. 6a,b). Western blot analysis of the xenograft 
tissue (treated with harmine) also showed a decreased expression of p-AKT and p-FOXO3A (Fig. 6b). We further 
analysed the levels of p-AKT (Ser473) and p-FOXO3A (Ser253) in CAL 27 cell line treated with DYRK1A siRNA. 
We observed a decreased phosphorylation of both p-AKT (Ser473) and p-FOXO3A (Ser253) in the siRNA treated 
cells (Fig. 6c). These results indicate that DYRK1A inhibition leads to activation of FOXO3A (decrease in phos-
phorylation) in HNSCC cells.
Discussion
We and others have demonstrated that phosphoproteomics is an effective technique to study aberrantly activated 
kinase signaling pathways in multiple malignancies8,29,30. There is substantial literature indicating that protein 
kinases are most frequently involved in tumorigenesis31. It is now well established that most cancers are heteroge-
neous and that specific kinases are hyperactive in at least a subset of a given cancers and drive their progression. 
Studies by us and others suggest that these activated kinases can serve as both surrogate markers for monitoring 
responses and also serve as potential therapeutic targets32,33.
To identify novel therapeutic targets in HNSCC, we studied the phosphotyrosine signaling in a panel of 
HNSCC cell lines and normal oral keratinocyte cell line OKF6/TERT1. This led to the identification of hyper-
phosphorylated kinases such as YES proto-oncogene 1, Src family tyrosine kinase (YES1), epidermal growth fac-
tor receptor (EGFR), LYN proto-oncogene (LYN), EPH receptor A2 (EPHA2) and DYRK1A in the HNSCC cell 
lines. DYRK1A is a member of the conserved family of DYRKs that autophosphorylate tyrosine in their activation 
loop34. Depending upon the cellular context, DYRK1A is known to function both as a tumor suppressor and an 
oncogene35. Recent studies have indicated the role of DYRKs in regulation of mitotic transition and apoptosis 
induced by DNA damage36. Various members of DYRK family have been reported to play key role in cell prolifer-
ation and survival in cancer cell lines. Pharmacological inhibition of DYRK1A in mouse xenograft based studies 
has demonstrated it as a potential target in Glioblastoma13. DYRK1A has been shown to play role in quiescence 
by the assembly of DREAM complex and inhibits cell proliferation37. Our data illustrates the role of DYRK1A in 
both proliferation and metastatic potential in HNSCC. Silencing and/or inhibition of DYRK1A using siRNA or 
inhibitor (harmine) showed an increased apoptosis with significant reduction in cellular proliferation, invasion 
and colony forming ability of the HNSCC cells. We observed a significant decrease in tumor load in mouse xen-
ografts upon DYRK1A inhibition. Our immunohistochemical studies indicate strong to moderate expression of 
DYRK1A in 97.5% of HNSCC primary tissue. These results suggest that DYRK1A has the potential to become a 
novel therapeutic target for HNSCC.
It has been reported that DYRK1A activates PI3K/AKT and MAPK pathways in conditions such as hyper-
homocystenimia23, however the connecting link between these major signaling pathways and DYRK1A remains 
unclear in cancer. It has been reported that FOXO transcription factors can be targeted by DYRK kinases24. 
FOXO transcription factors are known to play a role in regulating genes responsible for apoptosis and cell cycle 
progression38. They are mainly regulated by phosphorylation, acetylation and ubiquitination. Previous studies 
have shown that phosphorylation of FOXO3A by AKT and MAPK1/2 promotes cellular survival26,27. We studied 
the effect of DYRK1A inhibition in HNSCC cell lines. Our study demonstrates that inhibition of DYRK1A led 
to cell death via decrease in phosphorylation of FOXO3A which is both dependent and independent on AKT 
signaling in HNSCC cells. Taken together our data suggest the role of DYRK1A signaling in promoting cellular 
survival in HNSCC.
In summary this study shows that DYRK1A was hyperphosphorylated and overexpressed in HNSCC cells. We 
showed a decrease in oncogenic characteristics including proliferation, invasion and migration of cells by inhibition 
of DYRK1A using in vitro assays. Inhibition of DYRK1A in vivo also resulted in a reduction in tumor growth. Our 
results indicate that DYRK1A plays a crucial role in regulating major signaling pathways in HNSCC. These results 
suggest that DYRK1A plays an important role in carcinogenesis and can serve as a potential therapeutic target in 




p-value of significant difference 
between tumor and normal groups 
(Chi-square test)
0.0076
Table 2.  Summary of the immunohistochemical validation of DYRK1A in HNSCC and normal tissues.
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HNSCC. Future investigations in larger patient cohorts are required to confirm our findings in clinical settings. Our 
work provides a scaffold for future studies to systematically investigate the role of DYRK1A in HNSCC.
Methods
Cell culture. FaDu and CAL 27 were purchased from ATCC. Normal oral keratinocyte OKF6/TERT1 was a 
gift from Dr. James Rheinwald at Brigham and Women’s Hospital in Boston, MA. JHU-O11, JHU-O22, JHU-O28, 
JHU-O29 and FaDu were cultured in RPM1-1640 media supplemented with 10% fetal bovine serum and 1% pen-
icillin/streptomycin. CAL 27 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum 
and 1% penicillin/streptomycin. OKF6/TERT1 was cultured and maintained in KSFM (keratinocyte-serum free 
media) (Life Technologies, Grand Island, NY) supplemented with bovine pituitary extract (25 mg/ml), calcium 
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Figure 2. Inhibition of DYRK1A affects the colony forming ability of the HNSCC cells. (a) Colony 
formation assay following siRNA mediated knockdown of DYRK1A or control siRNA in a panel of HNSCC 
cell lines, as indicated. Colonies formed were visualized after staining with methylene blue. (b) A graphical 
representation of the colony forming ability of the HNSCC cells upon DYRK1A silencing (*p < 0.05). (c) Colony 
forming ability of the HNSCC cells upon inhibition of DYRK1A using harmine or control (DMSO), in the 
indicated panel of HNSCC cells. (d) A graphical representation of the colony forming ability of HNSCC cells 
upon harmine treatment (*p < 0.05). Representative images were photographed at a magnification (2.5x).
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chloride (0.4 mM), epidermal growth factor (0.2 ng/ml) and 1% penicillin/streptomycin. All cell lines were grown 
in a humidified incubator with 5% CO2 at 37 °C. The cell lines used for the study were authenticated by short 
tandem repeat analysis at the Genetic Resources Core Facility of Johns Hopkins University School of Medicine.
Sample Preparation for LC-MS/MS analysis. Protein isolation and digestion. Each cell line was grown 
to 70% confluence and then maintained in serum free medium for 12 h before the cells were harvested for protein 
isolation. The cells were lysed in lysis buffer (2% SDS, 5mM sodium fluoride, 1 mM β -glycerophosphate, 1mM 
sodium orthovanadate in 50mM Triethyl ammonium bicarbonate (TEABC)). Protein concentration was esti-
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Figure 3. Inhibition of DYRK1A reduces the invasive ability of the HNSCC cells. (a) HNSCC cells were 
transfected with DYRK1A specific siRNA and/or scramble siRNA and invasion assays were carried out using 
in a transwell system using Matrigel-coated filters and the number of cells that migrated to the lower chamber 
was counted. Cells that migrated are visualized following methylene blue staining in a panel of HNSCC cell lines 
as indicated and invaded cells were photographed. (b) Graphical representation of invasive ability of HNSCC 
cells upon DYRK1A silencing (*p < 0.05). (c) HNSCC cells were treated with DYRK1A inhibitor (harmine) 
or vehicle control (DMSO) and invaded cells were photographed. (d) Graphical representation of invasive 
ability of DYRK1A upon inhibition with harmine (*p < 0.05). Representative images were photographed at a 
magnification (10x).
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digestion. We employed filter aided sample preparation (FASP) protocol using 30kDa filters to reduce the amount 
of SDS in the lysate39. The protein sample was reduced and alkylated as described previously40. Trypsin digestion 
was carried using TPCK treated trypsin (1: 20) for 12–16 h at 37 °C.
TMT labeling and phosphopeptide enrichment. Peptide samples were labeled using TMT 10 plex reagents 
(Thermo Scientific, Bremen, Germany) as described previously41. Peptides derived from all OKF6/TERT1 were 
labeled with TMT tag 127N, JHU-O28 with 128C, JHU-O11 with 129N, FaDu with 129C, CAL 27 with 130N, 
JHU-O22 with 130C and JHU-O29 with 131. The labeled samples were pooled and loaded on to a Sep-Pak C18 
(Waters) column equilibrated with 0.1% TFA. The column was further washed with 0.1% TFA and the peptides 

































































Figure 4. Inhibition of DYRK1A suppresses tumor growth in vivo (a) CAL 27 (2 × 106) cells were injected into 
the flanks of female nude mice (n = 10) and tumor growth kinetics is represented for a period of 25 days.  
*p = 0.02 (b) Representative pictures of tumors from vehicle and harmine treated groups. (c) Bar graph 
representing the tumor weights (**p < 0.05). (d) Expression of Ki67 (Alexa Fluor 594) in xenograft tissue 
sections was determined by immunofluorescence. Cell nuclei were stained blue with 4′ ,6-diamidino-2-
phenylindole (DAPI).
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II) CAL 27 Harmine 












































































II) JHU - O28 Harmine 
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Figure 5. Inhibition of DYRK1A induces apoptosis in vitro and in vivo. Apoptosis was measured in CAL 
27 (a) and JHU-O28 (b) cells using Annexin V/PI staining. (c) Western blot analysis was carried out for the 
indicated proteins using CAL 27 and JHU-O28 cells treated with harmine or DMSO (control). β -actin was used 
as a loading control. (d) Western blot analysis was carried out using cellular lysates of xenograft tissue (Harmine 
and DMSO treated) for the indicated proteins. β -actin was used as a loading control.
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were eluted in 6 ml of 40% ACN with 0.1% TFA. Peptides were lyophilized and subjected to phosphopeptide 
enrichment. The enrichment of tyrosine phosphorylated peptides from TMT labeled lysates was carried out using 
Phosphoscan Kit (P-Tyr-1000, Cell signaling technology, Danvers, MA) as described previously29.
LC-MS/MS analysis. LTQ-Orbitrap Velos mass spectrometer interfaced with Proxeon Easy nLC system 
(Thermo Scientific, Bremen, Germany) was used for the analysis of TMT-labeled samples. The MS parameters 
used for analysis were followed as described previously40. Briefly, precursor MS scan (from m/z 350–1,700) and 
MS/MS was acquired with a mass resolution of 60,000 and 30,000 at 400 m/z in orbitrap mass analyzer. In each 
duty cycle ten most intense peaks were selected for MS/MS fragmentation using higher-energy collision dissoci-
ation mode at 45% normalized collision energy and isolation width was set to 1.9 m/z.
Data analysis. The Proteome Discoverer (Version 1.4.1.14) software suite (Thermo Scientific, Bremen, 
Germany) was used to carry out protein identification and quantitation. Mass spectrometry data was searched 
against NCBI Human RefSeq protein database (Version 65) supplemented with common contaminants using 
Mascot (version 2.2.0) and SEQUEST search algorithms. The search parameters included trypsin as the protease 
with maximum of 2 missed cleavage allowed; oxidation of methionine and phosphorylation of tyrosine, serine 
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Figure 6. Inhibition of DYRK1A leads to activation of FOXO3A in HNSCC. HNSCC cell lines JHU-O28, 
FaDu, JHU-O11, JHU-O29 (a) and CAL 27 (b) were treated with DYRK1A inhibitor harmine. Immunoblot 
analysis of p-AKT (Ser473), Total AKT, p-FOXO3A (Ser253) and Total FOXO3A was performed. β -actin was 
used as loading control. (b) Western blot analysis was performed using cellular lysates from xenograft tissue 
(Harmine and DMSO treated) for AKT (Ser473), Total AKT, p-FOXO3A (Ser253) and Total FOXO3A. (c) 
CAL 27 cells were treated with DYRK1A siRNA or control siRNA and Western blot analysis was carried for the 
indicated proteins.
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cysteine and TMT modification at N-terminus of the peptide and lysine. Precursor mass tolerance was set to 
10 ppm and fragment mass tolerance was set to 0.05 Da. The false discovery rate (FDR) was calculated by carrying 
out decoy database searches and peptides scoring better than 1% FDR score cut-off were considered for further 
analysis42. The ratios were calculated by the quantitation node and the phosphorylation probability was calculated 
using phosphoRS node in Proteome Discoverer.
Data availability. The mass spectrometry data is publicly available and accessible to other researchers. The 
complete mass spectrometry data generated from this study has been deposited to the ProteomeXchange (http://
www.proteomexchange.org) via PRIDE partner repository with the dataset identifier PXD002132. The immu-
nohistochemistry data was submitted to Human Proteinpedia43 and can be visualized with the link http://www.
humanproteinpedia.org/Experimental_details?exp_id= TE-552658 for adjacent non-neoplastic tissue and http://
www.humanproteinpedia.org/Experimental_details?can_id= 105424 for tumor tissues.
siRNA Transfection. ON-TARGETplus SMARTpool control siRNA and DYRK1A siRNA were purchased 
from Dharmacon (Lafayette, CO) and cells were transfected with control and DYRK1A siRNA using RNAiMAX 
reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions.
Cell proliferation assays. Cell proliferation assays was carried out as described previously with minor 
modifications40. The HNSCC cells were seeded at a density of 8000 cells/well into 96-well plate and treated with 
DYRK1A siRNA or its inhibitor harmine (20 μ M) for 72 h. Cell proliferation was determined using MTT (3-(4, 
5-dimethylthiazol-2yl)-2, 5-diphenyl tetrazolium bromide) assays as described44. Absorbance was measured at 
570 nm and 650 nm. All experiments were carried out in triplicates.
Colony formation assays. Colony formation assays were carried out as described previously with minor 
modifications45. HNSCC cell lines were seeded at a cell density of 8000 cells per well of a 6-well plate and trans-
fected with either DYRK1A siRNA or control siRNA. After 48 h of transfection, cells were seeded into 6 well 
plates. Cell colonies were allowed to grow for 10–14 days. The colonies formed were fixed with methanol and 
stained with 4% methylene blue. Similarly, colony formation was done in the presence of harmine, DYRK1A 
inhibitor. Colonies formed was counted for ten randomly selected viewing fields and representative images were 
photographed at 2.5x magnification. All experiments were carried out in triplicate.
Cell invasion assays. Invasion assays were performed in a transwell system (BD Biosciences) with 
Matrigel-coated filters, and cellular invasion was evaluated after 48 h as described previously45. Briefly, invasive-
ness of the cells was assayed in the membrane invasion culture system using polyethylene terephthalate (PET) 
membrane (8-μ m pore size) in the upper compartment of a transwell coated with Matrigel (BD BioCoat Matrigel 
Invasion Chamber; BD Biosciences). The cells were transfected with either control or DYRK1A siRNA and seeded 
at 2.0 × 104 cells per 500 μ l of media on the Matrigel-coated PET membrane in the upper compartment. The lower 
compartment was filled with complete growth media and the plates were maintained at 37 °C for 48 h. At the end 
of the incubation time, the upper surface of the membrane was wiped with a cotton-tip applicator to remove non 
migratory cells. Cells that migrated to bottom side of membrane were fixed and stained using 4% methylene blue. 
The number of cells that penetrated was counted for ten randomly selected viewing fields at 10x magnification. 
Similarly, invasion assay was carried out in the presence of harmine. Each measurement was performed in dupli-
cate and experiments were repeated three times.
In vivo studies. Subcutaneous xenografts were generated in 6-week-old athymic nu/nu female nude mice with 
CAL 27 (2 × 106) cells in both the flanks of mice. One week following tumor cell inoculation, ten mice with 
successfully engrafted CAL 27 xenografts (50 mm3) were randomized into two cohorts of five animals per group 
and were treated with either DMSO (Vehicle) or harmine (15 mg/kg/injection, every 3 days) intraperitoneally 
(i.p.). Harmine dosage was selected based on previous study13. Tumor size was measured after every 3 days using 
digital calipers (Fisher Scientific) upto four weeks and the mean tumor volume was calculated using the formula 
(π /6(d1xd2)3/2)46. All the animal experiments were approved by the Institutional Animal Care and Use Committee 
of Indian Institute of Sciences, Bangalore, India. All the experiments were performed in accordance with the rel-
evant guidelines and regulations.
Immunohistochemical assays. Immunohistochemical analysis using commercially available tissue 
microarray was carried out for DYRK1A. TMAs obtained commercially were processed and immunohistochemi-
cal staining was carried out as described previously47. Briefly, the formalin fixed paraffin embedded tissue sections 
were deparaffinised prior to antigen retrieval by addition of antigen retrieval buffer (citrate buffer) for 20 min. 
Action of endogenous peroxidases was quenched using blocking solution (methanol and H2O2 mixed at 3:1 ratio) 
and then washed with wash buffer (phosphate buffered saline). Polyclonal rabbit anti-DYRK1A antibody (Cat 
#: sc-28899, Santa cruz biotechnology, Santa cruz, CA) was used as a primary antibody at a dilution of 1:50. The 
sections were incubated overnight with primary antibody at 4 °C. Then the sections were rinsed with wash buffer 
followed by incubation with rabbit secondary antibody conjugated horseradish peroxidase (Merck-Banglore Genei, 
India). The staining was developed for 5 min using DAB chromogen (Dako, Glostrup, Denmark), followed by coun-
terstaining with hematoxylin (Nice Chemicals, Kochi, India). The tissue sections were then examined under the 
microscope by pathologist and the immunohistochemical labeling was assessed to score the intensity of staining. The 
staining was scored on a scale of 0–2, where 0 represented absent staining, + 1 represented faint staining and + 2 rep-
resented intense staining. Cases that were + 2 were considered as highly stained cases. A chi-square test was carried 
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out to determine the significance of the immunohistochemistry results. Xenograft tissue sections were examined for 
the expression of Ki67 marker by immunofluorescence and Western blot analysis.
Western blot analysis. Cells were cultured to 70% confluency and the proteins were harvested in RIPA 
lysis buffer (10 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton-X-100, 0.1% SDS containing protease 
and phosphatase inhibitor cocktails) and sonicated. Western blot analysis was carried out as described previ-
ously45,48. Polyclonal rabbit anti-DYRK1A antibody was obtained from Santa cruz (Santa cruz biotechnology). 
Anti- FOXO3A, anti-AKT, anti-phospho FOXO3A (Ser 253) and anti-phospho-AKT (Ser 473) antibodies were 
obtained from Cell Signaling Technology (Cell Signaling Technology, Beverly, MA). Beta-actin antibody was 
obtained from Sigma (St. Louis, MO).
Annexin V/PI staining. Apoptosis was determined by staining cells with annexin Vfluorescein isothiocy-
anate (FITC) and PI labeling as per manufacturer’s instructions (Becton Dickinson, Franklin Lakes, NJ). Briefly, 
JHU-O28 and CAL 27 cells were treated with or without harmine. The prepared cells were washed twice with cold 
PBS, resuspended in 1 ml of binding buffer. 100 ul of the resuspended culture is stained with Annexin V and PI. 
The cells were analyzed on the BD FACSVerseTM flow cytometer (Becton Dickinson, Franklin Lakes, NJ). Data 
analysis was done using “FlowJo” software.
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Additionally in Figure 4b, the label ‘Harmine (15 mg/kg)’ is incorrectly given as ‘Harmine (30 mg/kg)’. The correct 
Figure 4 appears below as Figure 1.
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Figure 1.  
